



NIH SCIENTIFIC MANAGEMENT REVIEW BOARD



Translational Medicine and Therapeutics Working Group

ROSTER

Non-Federal Members

Arthur H. Rubenstein, M.B.B.Ch.
(Chair)

Executive Vice President, University of Pennsylvania for the Health System and Dean, University of Pennsylvania School of Medicine, Philadelphia, PA

William R. Brody, M.D., Ph.D.
President, Salk Institute for Biological Studies, La Jolla, CA

Gail H. Cassell, Ph.D.
Vice President, Scientific Affairs, Eli Lilly and Company, Indianapolis, IN

William L. Roper, M.D., M.P.H.
Dean of the School of Medicine, Vice Chancellor for Medical Affairs, and CEO of the UNC Health Care System, University of North Carolina Chapel Hill, NC

Solomon H. Snyder, M.D.
Professor of Neuroscience, Pharmacology and Molecular Sciences, and Psychiatry, Johns Hopkins University
Baltimore, MD

Huda Y. Zoghbi, M.D.
Professor and Howard Hughes Medical Institute Investigator, Baylor College of Medicine, Houston, TX

Norman Augustine *ad hoc*
Retired Chairman and CEO
Lockheed Martin Corporation
Bethesda, MD

Federal Members

Josephine P. Briggs, M.D.
Director, National Center for Complementary and Alternative Medicine, NIH, Bethesda, MD

Anthony Fauci, M.D.
Director, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD

Eric D. Green, M.D., Ph.D.
Director, National Human Genome Research Institute, NIH, Bethesda, MD

Stephen Katz, M.D., Ph.D.
Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases
NIH, Bethesda, MD

Griffin P. Rodgers, M.D., M.A.C.P.
Director, National Institute of Diabetes and Digestive and Kidney Diseases, NIH
Bethesda, MD

Susan Shurin, M.D.
Acting Director, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD

Harold Varmus, M.D.
Director
National Cancer Institute, NIH
Bethesda, MD

Francis S. Collins, M.D., Ph.D.
nonvoting, ex officio
Director, NIH
Bethesda, MD